Levonorgestrel Ethinyl Estradiol

This page contains recent news articles, when available, and an overview of Levonorgestrel Ethinyl Estradiol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

BUYINS.NET: (WYE) SqueezeTrigger Price is $48.060. There is ...  -  ‎Aug 28, 2009‎
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release)

99% Effective NuvaRing(R) Now Available In The UK2  -  Jan 26, 2009
Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. American Journal of Obstetrics Medical News Today (press release),

FDA Approves Duramed's LoSEASONIQUE Oral Contraceptive  -  Oct 27, 2008
...for LoSEASONIQUE (levonorgestrel/ethinyl estradiol tablets 0.10 mg/0.02 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive. eMaxHealth.com,

FDA Approvals: Apidra, LoSeasonique, Precedex  -  Nov 6, 2008
On October 24, the FDA approved an oral contraceptive system consisting of levonorgestrel/ethinyl estradiol 0.1-mg/0.02-mg tablets and ethinyl estradiol Medscape (registration)

BUYINS.NET: (WYE) SqueezeTrigger Price is $44.892. There is ...  -  Jul 23, 2008
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

BUYINS.NET: (WYE) SqueezeTrigger Price is $44.287. There is ...  -  Jun 17, 2008
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

Wyeth Sues Sandoz to Block Generic Lybrel  -  Jun 9, 2008
Sandoz infringed on the ’814 patent with its ANDA’s Paragraph IV certification to make a generic version of Lybrel (levonorgestrel/ethinyl estradiol). FDA news (subscription),

BUYINS.NET: (WYE) SqueezeTrigger Price is $43.778. There is ...  -  May 28, 2008
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

Barr’s Lo Seasonique Contraceptive to See Decision in Fall  -  Mar 4, 2008
If approved, Barr subsidiary Duramed’s Lo Seasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) would be the first lower-dose, FDA news (subscription),

Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA  -  Feb 26, 2008
...for Lo SEASONIQUE(R) (levonorgestrel/ethinyl estradiol tablets 0.10 mg/0.02 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive. FOXBusiness

Watson Files Application For Generic Seasonique - Quick Facts  -  Mar 4, 2008
...(RTTNews) - Watson Pharmaceuticals Inc. (WPI | news | PowerRating | PR Charts ) confirmed that it has filed an Abbreviated New Drug Application or ANDA with Trading Markets (press release),

SEASONIQUE(R) Patent Issues  -  Jan 23, 2008
The Company received FDA approval for SEASONIQUE (levonorgestrel/ethinyl estradiol tablets 0.15 mg/0.03 mg and ethinyl estradiol tablets 0.01 mg) CNNMoney.com

BUYINS.NET: (WYE) SqueezeTrigger Price is $47.721. There is ...  -  Jan 9, 2008
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

Watson Confirms Patent Litigation With Barr Related to Seasonale(R)  -  Dec 14, 2007
Inc., has filed a patent lawsuit against Watson and certain of its subsidiaries related to Quasense(TM) (levonorgestrel/ethinyl estradiol tablets USP), CNNMoney.com

BUYINS.NET: (WYE) SqueezeTrigger Price is $46.961. There is ...  -  Nov 27, 2007
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

Is it safe to have no menstrual cycle with birth control pills  -  Nov 13, 2007
US Food & Drug Administration (FDA) has approved Lybrel (levonorgestrel and ethinyl estradiol) on May 22, 2007, which is the first low-dose combination oral PR-USA.net (press release),

BUYINS.NET: (WYE) squeezetrigger Price is $46.961. There is ...  -  Nov 14, 2007
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

BUYINS.NET: (WYE) squeezetrigger Price is $46.959. There is ...  -  Oct 23, 2007
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

Wyeth still confident it can overcome regulatory setbacks  -  Oct 22, 2007
...drugs this year – its first-in-class renal cancer drug Torisel (temsirolimus) and the oral contraceptive Lybrel (levonorgestrel/ethinyl estradiol). Pharma Times (subscription),

BUYINS.NET: (WYE) SqueezeTrigger Price is $46.970. There is ...  -  Oct 4, 2007
In May 2005, the Company filed a NDA with the FDA for LYBREL (levonorgestrel/ethinyl estradiol), an oral contraceptive with a continuous dosing regimen. Trading Markets (press release),

FDA Approves Continuous-Use Contraceptive  -  May 24, 2007
Facts and Comparisons,The FDA has approved Wyeth Laboratories’ Lybrel (levonorgestrel 90 mcg/ ethinyl estradiol 20 mcg), the first continuous-use oral drug product for prevention

Market Report -- In Play (WYE)  -  May 22, 2007
MSN MoneyWyeth announced FDA approves Lybrel, first low dose combination oral contraceptive offering women the opportunity to be period-free over time Co announced

FDA Approves Duramed's SEASONIQUE(TM) Extended-Cycle Oral ...  -  Apr 12, 2007
Drug Newswire (press release),Inc.'s New Drug Application (NDA) for SEASONIQUE(TM) (levonorgestrel/ethinyl estradiol tablets 0.15 mg/0.03 mg and ethinyl estradiol tablets 0.01 mg)

Studies Examine Menopause Treatments, Oral Contraception To ...  -  Jan 2, 2007
Medical News Today (press release),..."Evaluation of a Continuous Regimen of Levonorgestrel/Ethinyl Estradiol: Phase 3 Study Results," Contraception : David Archer, a Wyeth consultant from the

Studies Examine Menopause Treatments, Oral Contraception to ...  -  Dec 22, 2006
Kaiser network.org,..."Evaluation of a Continuous Regimen of Levonorgestrel/Ethinyl Estradiol: Phase 3 Study Results," Contraception : David Archer, a Wyeth consultant from the

Shire plc: Excellent Third Quarter With Execution Plan on Track ...  Oct 27, 2006
...women's health products, as well as a license to Duramed's currently marketed oral contraceptive, SEASONIQUE® (levonorgestrel/ethinyl estradiol tablets 0.15 mg ... -Yahoo! News (press release) Shire plc: Excellent Third Quarter With Execution Plan on Track ...  Oct 27, 2006
...women's health products, as well as a license to Duramed's currently marketed oral contraceptive, SEASONIQUE(R) (levonorgestrel/ethinyl estradiol tablets 0.15 ... -PR Newswire (press release), Pill to end misery of PMS  Oct 24, 2006
The new pill, Lybrel (levonorgestrel / ethinyl estradiol), is designed to be taken every day and has been shown to reduce breast pain and nausea. ... -Daily Mail - UK, First-Time Generic Approvals: Seasonale, Imodium Advanced, and ...  Sep 22, 2006
...the trade name Jolessa. Levonorgestrel/ethinyl estradiol is indicated for contraceptive use in women. The extended-cycle regimen ... -Medscape (subscription)

Weekly Wrap-up - Pharma Sector: Genta's Genasense Gets Knockout ...  Sep 10, 2006
In May 2006, Barr received approval for its SEASONIQUE (levonorgestrel/ethinyl estradiol tablets 0.15 mg/0.03 mg and ethinyl estradiol tablets 0.01 mg) extended ... -Trading Markets

Shire plc: IFRS Information - First Half of 2006  Sep 18, 2006
...women's health products, as well as a license to Duramed's currently marketed oral contraceptive, Seasonique ( levonorgestrel/ethinyl estradiol tablets 0.15 mg ... -PR Newswire

Watson Pharmaceuticals Receives FDA Final Approval for Generic ...  Sep 8, 2006
...from the United States (US) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel / ethinyl estradiol tablets USP ... -PipelineReview.com

Shire and Barr Settle All Pending Litigation Concerning ADDERALL ...  Aug 14, 2006
...women's health products, as well as a license to Duramed's currently marketed oral contraceptive, Seasonique (levonorgestrel/ethinyl estradiol tablets 0.15 mg ... -Finanzen.net

Barr & Shire Sign Three Agreements  Aug 15, 2006
...regulatory approval for and market in certain specified territories Duramed's recently approved SEASONIQUE (levonorgestrel/ethinyl estradiol tablets 0.15 mg ... -ag-IP-news Agency

Parties Agree to Settle Pending Patent Litigation Regarding ...  Aug 14, 2006
...regulatory approval for and market in certain specified territories Duramed's recently approved SEASONIQUE(TM) (levonorgestrel/ethinyl estradiol tablets 0.15 mg ... -Yahoo! News

Shire settles with Barr over Adderall XR  Aug 15, 2006
...by Barr's Duramed subsidiary, as well as a license for Duramed's already-marketed oral contraceptive Seasonique (levonorgestrel/ethinyl estradiol) in the five ... -Pharma Times (subscription)

Wyeth Reports Earnings Results for the 2006 Second Quarter and ...  Jul 20, 2006
The Company also expects approval of LYBREL(TM) (levonorgestrel/ethinyl estradiol), a novel continuous regimen oral contraceptive for which Wyeth received an ... -PR Newswire

Watson Pharma's Generic Seasonale Gets Tentative FDA Approval ...  May 9, 2006
...approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for levonorgestrel / ethinyl estradiol tablets USP, 0.15 ... - Trading Markets

New Findings From Two Studies on Lybrel Presented at ACOG  May 8, 2006
Abstract: Comparative Trial of Continuous-Use and 21-Day Cyclic Levonorgestrel/Ethinyl Estradiol Oral Contraceptives This scientific abstract reported on the ... - PR Newswire

Watson Pharmaceuticals Receives FDA Tentative Approval for Generic ...  May 9, 2006
...today from the United States (US) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel / ethinyl estradiol tablets USP ... - Yahoo! News

Watson 1Q profit drops 35 percent  May 9, 2006
...exchange. Levonorgestrel/ethinyl estradiol tablets USP is the generic equivalent to Duramed Pharmaceuticals' Seasonale tablets. ... - BusinessWeek

Watson nears OK on generic Seasonale  May 9, 2006
The company said the Food and Drug Administration has given its tentative clearance to its applications for levonorgestrel/ethinyl estradiol tablets 0.15 mg ... - United Press International

Wyeth Reports Earnings Results for the 2006 First Quarter  Apr 21, 2006
The Company expects approval of LYBREL(TM) (levonorgestrel/ethinyl estradiol), a new oral contraceptive with a unique dosing regimen, in the coming months and ... - MSN Money

Barr's Duramed Withdraws NDA for Lo SEASONALE(R) Extended-Cycle ...  Apr 6, 2006
...its subsidiary, Duramed Pharmaceuticals, Inc., has withdrawn its New Drug Application (NDA) for Lo SEASONALE® (levonorgestrel/ethinyl estradiol tablets 0.10 mg ... - Yahoo! News

Pipeline Insight: Anxiety Disorders - A decade of declining ...  Mar 28, 2006
III for GAD, and Schering AG/Berlex's YAZ (low dose drospirenone/ethinyl estradiol) and Wyeth's Librel (low dose levonorgestrel/ethinyl estradiol), both in ... - Pharmaceutical Business Review

Barr Confirms that Additional Clinical Data Is Not Required for ...  Mar 17, 2006
...to support the approval of Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for SEASONIQUE(TM) (levonorgestrel/ethinyl estradiol tablets 0.15 mg/0.03 ... - PR Newswire

Wyeth Reports Earnings Results for the 2005 Fourth Quarter and ... Jan 31, 2006
In May, Wyeth submitted an application for LYBREL(TM) (levonorgestrel/ethinyl estradiol), a new oral contraceptive with a unique dosing regimen; in December ... - PR Newswire,

Wyeth Reports Earnings Results for the 2005 Fourth Quarter and ...  Jan 31, 2006
In May, Wyeth submitted an application for LYBREL(TM) (levonorgestrel/ethinyl estradiol), a new oral contraceptive with a unique dosing regimen; in December ... - MSN Money

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.

IF YOU NEED A LINK/TEXT REMOVED FROM THIS PAGE, PLEASE CONTACT: mongabay (at) gmail.com